At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
abicipar pegol +2 moredrug
Likely dose
ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating abicipar pegol, ranibizumab, and 1 other intervention for Macular Degeneration. Completed, enrolled 25 participants across 11 sites.
Detailed Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartSep 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedJul 4, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.0 years ago
Interventions
abicipar pegoldrug
Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
ranibizumabdrug
Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
sham procedureother
Sham procedure to the study eye at weeks 12 and 16.